HK2 and neoplasm: For instance, target metabolic reprogramming features by combining glycolysis inhibitors (e.g., HK2 inhibitors) with PD-1 inhibitors to enhance immunotherapy efficacy by ameliorating metabolic dysregulation in the tumor microenvironment; for HER2-positive patients, combining disitamab vedotin with immune checkpoint inhibitors has shown ORR increased to over 60% in clinical studies.